Teva shares plunge over exposure to opioid suits; CFO quits

Teva stock has slightly rebounded after hitting a 52-week low earlier Wednesday after the Israeli pharmaceutical giant said it was setting aside $646 million for opioid painkiller settlements.

The Petah Tikva-based drugmaker reported slightly better than expected non-GAAP earnings of $0.60.

Shares slipped over 9.5% to a yearly low of $6.34, before rebounding to $6.90.  Once Israel’s largest company, the generics maker has seen its share price plummet from over $25 in the last year, amid concerns over lost market position and exposure to lawsuits stemming from its prescription painkillers.

Teva CFO Michael McClellan said earlier Wednesday that he was stepping down for personal reasons, according to the Wall Street Journal.

Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
Register for free
and continue reading
Registering also lets you comment on articles and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure:
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.